Investigating Neurocognitive Disorders Epidemiology

Launched by KING CHULALONGKORN MEMORIAL HOSPITAL · Apr 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how to predict the progression of neurocognitive disorders, such as dementia and Alzheimer’s disease, in the Thai population. Researchers will look at two main factors: levels of a specific protein in the blood called phosphorylated tau (p-tau) and scores from cognitive tests that measure thinking abilities. They hope to find out how these factors can help diagnose these conditions, understand their effects on patients’ lives, and the broader impact on society.

The study is currently recruiting participants of all ages who can speak and understand Thai without needing a translator. There are different groups of people who may be eligible: those who are cognitively healthy, those with mild cognitive impairment, and individuals with early or late-onset dementia. Participants will undergo cognitive tests, have interviews, and may provide blood samples for research. They will also have follow-up visits each year or every two years to monitor changes over time. This trial aims to deepen our understanding of neurocognitive disorders, which can greatly affect individuals and families.

Gender

ALL

Eligibility criteria

• • 1. Cognitively Healthy Individuals
• • INCLUSION CRITERIA
• • Demonstrate normal cognitive function within the expected range on objective cognitive tests.
• • Proficient in speaking and understanding Thai without the need for a translator to participate.
• • EXCLUSION CRITERIA
• • Significant neurological or uncontrolled psychiatric illness.
• • Significant unstable systemic condition or end-stage organ failure that affects study participation.
• • 2. Mild Cognitive Impairment
• • INCLUSION CRITERIA
• • Display impaired/abnormal performance on objective cognitive tests.
• • Does not meet criteria for dementia per NIA-AA (or major neurocognitive disorder per DSM-5).
• • Proficient in speaking and understanding Thai without the need for a translator to participate.
• • EXCLUSION CRITERIA
• • Significant neurological or uncontrolled psychiatric illness.
• • Significant unstable systemic condition or end-stage organ failure that affects study participation.
• • 3. Late Onset Dementia
• • INCLUSION CRITERIA
• • Display impaired/abnormal performance on objective cognitive tests.
• • Meets criteria for dementia per NIA-AA (or major neurocognitive disorder per DSM-5), including dementia due to Alzheimer's disease or other causes.
• • Begins to experience symptoms, identified by the physician as a part of dementia continuum, occurring after the age of 65.
• • Proficient in speaking and understanding Thai without the need for a translator to participate.
• • EXCLUSION CRITERIA
• • Significant neurological or uncontrolled psychiatric illness.
• • Significant unstable systemic condition or end-stage organ failure that affects study participation.
• • 4. Early Onset Dementia
• • INCLUSION CRITERIA
• • Display impaired/abnormal performance on objective cognitive tests.
• • Meets criteria for dementia per NIA-AA (or major neurocognitive disorder per DSM-5), including dementia due to Alzheimer's disease or other causes.
• • Begins to experience symptoms, identified by the physician as a part of dementia continuum, occurring before the age of 65.
• • Proficient in speaking and understanding Thai without the need for a translator to participate.
• • EXCLUSION CRITERIA
• • Significant neurological or uncontrolled psychiatric illness.
• • Significant unstable systemic condition or end-stage organ failure that affects study participation.